Evidence map›Paper›PMID 40634091›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Efficacy of Azacitidine Plus Venetoclax in Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome after Failure of Azacitidine Monotherapy.

Takafumi Furumoto, Koji Ando, Eo Toriyama, Tomoko Hata, Shinichi Katsuoka, Saori Nishimura, Masamitsu Ichinose, Miki Hashimoto, Machiko Fujioka, Chika Sakaki and 25 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Takafumi FurumotoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Koji AndoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.
Eo ToriyamaDepartment of Hematology, Nagasaki University Hospital, Japan.
Tomoko HataDepartment of Laboratory Medicine, Nagasaki Harbor Medical Center, Japan.
Shinichi KatsuokaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Saori NishimuraDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Masamitsu IchinoseDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Miki HashimotoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Machiko FujiokaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Chika SakakiDepartment of Hematology, NHO Nagasaki Medical Center, Japan.
Hikaru SakamotoDepartment of Hematology, Nagasaki University Hospital, Japan.
Masahiko ChiwataDepartment of Hematology, Japan Community Health Care Organization Isahaya General Hospital, Japan.
Rena KamijoDepartment of Hematology, Sasebo City General Hospital, Japan.
Yuji KobayashiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Hideaki KitanosonoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Jun NakashimaDepartment of Hematology, Japan Community Health Care Organization Isahaya General Hospital, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Japan.
Masataka TaguchiDepartment of Hematology, Nagasaki University Hospital, Japan.
Makiko HoraiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.
Masatoshi MatsuoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.
Junya MakiyamaDepartment of Hematology, Sasebo City General Hospital, Japan.
Hidehiro ItonagaTransfusion and Cell Therapy Unit, Nagasaki University Hospital, Japan.
Shinya SatoDepartment of Hematology, Nagasaki University Hospital, Japan.
Maki BabaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.
Yasushi SawayamaDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.
Yumi TakasakiDepartment of Internal Medicine, Saint Francis Hospital, Japan.
Jun TaguchiDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.
Daisuke ImanishiDepartment of Internal Medicine, Nagasaki Prefecture Gotochuoh Hospital, Japan.
Yoshitaka ImaizumiDepartment of Hematology, NHO Nagasaki Medical Center, Japan.
Yasuhisa KawaguchiDepartment of Internal Medicine, NHO Nagasaki National Hospital, Japan.
Hideki TsushimaDepartment of Hematology, Nagasaki Harbor Medical Center, Japan.
Tatsuro JoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.
Shinichiro YoshidaDepartment of Hematology, NHO Nagasaki Medical Center, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Hospital, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Patients with acute myeloid leukemia (AML) transformed from myelodysplastic syndrome (MDS) have a poor prognosis, including those treated with azacitidine during the MDS phase; there is no standard for the care of these patients. Recently, azacitidine plus venetoclax (AZA/VEN) was reported to prolong the survival in treatment-naïve AML patients compared with AZA monotherapy. However, the results of AZA/VEN for AML transformed from MDS, particularly after AZA monotherapy, remain unclear. The present study therefore compared the clinical results of AZA/VEN treatment in these patients. Methods Data from MDS patients diagnosed at 10 institutions in Nagasaki Prefecture were collected. Thereafter, patients with transformed AML following AZA monotherapy during the MDS phase were selected, and their treatment response and survival were analyzed. Results The overall response (OR) rate, overall survival (OS), and event-free survival (EFS) were compared among patients treated with AZA/VEN (n=13), chemotherapy (intensive and low-intensity, n=35), AZA monotherapy (mAZA, n=15), and best supportive care (BSC, n=43) after AML transformation. The corresponding OR rates were 38.5%, 20.0%, and 6.7% for the AZA/VEN, chemotherapy, and mAZA groups, respectively (p=0.235). The respective median OS and EFS were 10.7 and 8.9 months for AZA/VEN, 3.2 and 2.0 months for chemotherapy, and 3.8 and 2.7 months for mAZA, and 1.7 months for BSC (OS only) (p=0.000023 for the OS and p=0.026 for the EFS), Conclusion Our findings suggest the superiority of AZA/VEN for AML patients with transformation from MDS following AZA monotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSulfonamidesAdultAgedAged, 80 and overAntimetabolites, AntineoplasticFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntimetabolites, AntineoplasticAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxacute myeloid leukemiaazacitidinemyelodysplastic syndromesvenetoclax

Identifiers

PMID40634091
PMCPMC12945404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.